Partnering with Sichuan Taienkang Pharmaceutical to expand into the global market for pharmaceutical intermediates.

Our company established a long-term, stable strategic partnership with Sichuan Tainkang Pharmaceutical Co., Ltd. on 2026/5/28. We will leverage complementary strengths in pharmaceutical intermediates to serve global drug clients together.

Sichuan Tainkang Pharmaceutical Co., Ltd. is a leading domestic manufacturer of pharmaceutical intermediates, equipped with advanced synthesis technologies and a rigorous quality management system. The company specializes in producing amino acid derivatives, heterocyclic compounds, and chiral intermediates, which are widely used in anticancer, antiviral, and cardiovascular drugs.

This collaboration is driven by the growing global demand for high-quality pharmaceutical intermediates. As innovative drug development advances and the generic drug market expands rapidly, pharmaceutical companies worldwide are increasingly demanding higher quality, purity, and stability from these intermediates. Qingyuan Huajing International Trade Co., Ltd. leverages its global sales network and professional supply chain capabilities to form a complementary partnership with Taienkang Pharmaceutical.

Per the agreement, Tyencon Pharmaceutical will serve as the core supplier for Qingyuan Huajing International Trade Co., Ltd., ensuring priority product supply and consistent quality. Both parties will establish a long-term, stable partnership to jointly develop international markets. Tyencon Pharmaceutical will provide technical support and quality assurance to Qingyuan Huajing International Trade Co., Ltd., helping customers make the most of their products.

"Our company states: 'Tainkang Pharmaceutical is a key strategic partner. Over the years, Tainkang has provided us with high-quality pharmaceutical intermediates, earning the trust of our global clients. By establishing this long-term partnership, we will further integrate our respective strengths to expand into international markets and achieve mutual benefit.'"

A representative of Taien Kang Pharmaceutical stated: "Qingyuan Huajing International Trade Co., Ltd. possesses extensive global client resources and professional service capabilities. Through this collaboration, our pharmaceutical intermediate products will better access international markets to serve global pharmaceutical clients. We are committed to continuously enhancing product quality and production capacity to provide stronger support to our partners."

This collaboration also includes technical exchanges, market information sharing, and joint participation in international expos across multiple areas. Both parties will establish a regular communication mechanism to ensure smooth progress of the cooperation projects. In the second half of 2026, both sides plan to jointly attend the European Pharmaceutical Ingredients Expo and the US Pharma Expo to showcase their collaboration achievements and latest products.

Industry analysts note that this partnership aligns with the pharmaceutical sector's broader trend of resource integration and collaborative growth. As the global pharmaceutical industry continues to expand, demand for high-quality intermediates is expected to rise. This collaboration is poised to deliver significant commercial value to both parties while advancing the development of the global pharmaceutical landscape.